Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Part D Cost Trends: A Good News/Bad News Story For Biopharma

Executive Summary

Despite headlines about soaring drug costs, Medicare Part D beneficiaries are not seeing much if any increase in their out-of-pocket spending. But that doesn’t necessarily mean that costs of the program are stable – which could open up a new area for policy activity in 2017 and beyond.

You may also be interested in...



Medicare Part D Catastrophic Spending Surge Needs Solutions, OIG Says

HHS Office of Inspector General joins legislators and policy experts in warning about sharp increases in Medicare spending on catastrophic coverage in Part D.

Paying For Cures Requires Bigger Budgets, Not Lower Drug Prices – Execs

Payors need to adopt a longer-term focus on coverage policies for prescription drugs and biologics that recognizes the benefits of covering high-priced, but often curative, treatments like those for hepatitis C, panelists argue at AEI-sponsored event.

Part D Reform Proposals From MedPAC May Find Traction After Election

Advisory group’s cost control recommendations on reinsurance, partial fills, and preferred specialty tiers could end up on the legislative agenda, particularly if Hillary Clinton is president.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS118896

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel